{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:05:45Z","timestamp":1782907545620,"version":"3.54.5"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIH NIA"},{"name":"CODI University of Antioquia"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To promote the development of effective therapies, there is an important need to characterize the full spectrum of neuropathological changes associated with Alzheimer\u2019s disease. In line with this need, this study examined white matter abnormalities in individuals with early-onset autosomal\u00a0dominant Alzheimer\u2019s disease, in relation to age and symptom severity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a cross-sectional analysis of data collected in members of a large kindred with a <jats:italic>PSEN1<\/jats:italic> E280A mutation. Participants were recruited between September 2011 and July 2012 from the Colombian Alzheimer\u2019s Prevention Initiative registry. The studied cohort comprised 50 participants aged between 20 and 55\u00a0years, including 20 cognitively unimpaired mutation carriers, 9 cognitively impaired mutation carriers, and 21 non-carriers. Participants completed an MRI, a lumbar puncture for cerebrospinal fluid collection, a florbetapir PET scan, and neurological and neuropsychological examinations. The volume of white matter hyperintensities (WMH) was compared between cognitively unimpaired carriers, cognitively impaired carriers, and non-carriers. Relationships between WMH, age, and cognitive performance were further examined in mutation carriers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The mean (SD) age of participants was 35.8 (9.6) years and 64% were women. Cardiovascular risk factors were uncommon and did not differ across groups. Cognitively impaired carriers [median, 6.37; interquartile range (IQR), 9.15] had an increased volume of WMH compared to both cognitively unimpaired carriers [median, 0.85; IQR, 0.79] and non-carriers [median, 1.07; IQR, 0.71]. In mutation carriers, the volume of WMH strongly correlated with cognition and age, with evidence for an accelerated rate of changes after the age of 43\u00a0years, 1\u00a0year earlier than the estimated median age of symptom onset. In multivariable regression models including cortical amyloid retention, superior parietal lobe cortical thickness, and cerebrospinal fluid phospho-tau, the volume of WMH was the only biomarker independently and significantly contributing to the total explained variance in cognitive performance.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The volume of WMH is increased among individuals with symptomatic autosomal-dominant Alzheimer\u2019s disease, begins to increase prior to clinical symptom onset, and is an independent determinant of cognitive performance in this group. These findings suggest that WMH are a key component of autosomal-dominant Alzheimer\u2019s disease that is closely related to the progression of clinical symptoms.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13195-022-01030-7","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T13:04:58Z","timestamp":1656507898000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["White matter hyperintensities are a prominent feature of autosomal\u00a0dominant Alzheimer\u2019s disease that emerge prior to dementia"],"prefix":"10.1186","volume":"14","author":[{"given":"Dorothee","family":"Schoemaker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Clara","family":"Zanon Zotin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kewei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay C.","family":"Igwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Vila-Castelar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jairo","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Baena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua T.","family":"Fox-Fuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Lopera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Reiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam M.","family":"Brickman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakeel T.","family":"Quiroz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,29]]},"reference":[{"issue":"11","key":"1030_CR1","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.ajpath.2021.07.004","volume":"191","author":"RN Kalaria","year":"2021","unstructured":"Kalaria RN, Sepulveda-Falla D. Cerebral small vessel disease in sporadic and familial Alzheimer disease. Am J Pathol. 2021;191(11):1888\u2013905.","journal-title":"Am J Pathol"},{"issue":"1","key":"1030_CR2","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/WAD.0000000000000215","volume":"32","author":"KJ Bangen","year":"2018","unstructured":"Bangen KJ, Preis SR, Delano-Wood L, Wolf PA, Libon DJ, Bondi MW, et al. Baseline white matter hyperintensities and hippocampal volume are associated with conversion from normal cognition to mild cognitive impairment in the Framingham Offspring Study. Alzheimer Dis Assoc Disord. 2018;32(1):50.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"s4","key":"1030_CR3","doi-asserted-by":"publisher","first-page":"S393","DOI":"10.3233\/JAD-141473","volume":"42","author":"M Mortamais","year":"2014","unstructured":"Mortamais M, Artero S, Ritchie K. White matter hyperintensities as early and independent predictors of Alzheimer\u2019s disease risk. J Alzheimers Dis. 2014;42(s4):S393\u2013400.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"1030_CR4","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.bbadis.2011.07.009","volume":"1822","author":"BT Gold","year":"2012","unstructured":"Gold BT, Johnson NF, Powell DK, Smith CD. White matter integrity and vulnerability to Alzheimer\u2019s disease: preliminary findings and future directions. Biochim Biophys Acta. 2012;1822(3):416\u201322.","journal-title":"Biochim Biophys Acta"},{"issue":"6","key":"1030_CR5","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/ana.24647","volume":"79","author":"S Lee","year":"2016","unstructured":"Lee S, Viqar F, Zimmerman ME, Narkhede A, Tosto G, Benzinger TL, et al. White matter hyperintensities are a core feature of Alzheimer\u2019s disease: evidence from the dominantly inherited Alzheimer network. Ann Neurol. 2016;79(6):929\u201339.","journal-title":"Ann Neurol"},{"issue":"10","key":"1030_CR6","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1093\/brain\/awy229","volume":"141","author":"M\u00c1 Araque Caballero","year":"2018","unstructured":"Araque Caballero M\u00c1, Su\u00e1rez-Calvet M, Duering M, Franzmeier N, Benzinger T, Fagan AM, et al. White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer\u2019s disease. Brain. 2018;141(10):3065\u201380.","journal-title":"Brain"},{"issue":"3","key":"1030_CR7","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1093\/brain\/115.3.735","volume":"115","author":"P Scheltens","year":"1992","unstructured":"Scheltens P, Barkhof F, Valk J, Algra P, van der Hoop RG, Nauta J, et al. White matter lesions on magnetic resonance imaging in clinically diagnosed Alzheimer\u2019s disease: evidence for heterogeneity. Brain. 1992;115(3):735\u201348.","journal-title":"Brain"},{"issue":"3","key":"1030_CR8","doi-asserted-by":"publisher","first-page":"827","DOI":"10.3233\/JAD-150899","volume":"51","author":"R Sanchez-Valle","year":"2016","unstructured":"Sanchez-Valle R, Monte GC, Sala-Llonch R, Bosch B, Fortea J, Llado A, et al. White matter abnormalities track disease progression in PSEN1 autosomal dominant Alzheimer\u2019s disease. J Alzheimers Dis. 2016;51(3):827\u201335.","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"1030_CR9","doi-asserted-by":"publisher","first-page":"e0195838","DOI":"10.1371\/journal.pone.0195838","volume":"13","author":"S Lee","year":"2018","unstructured":"Lee S, Zimmerman ME, Narkhede A, Nasrabady SE, Tosto G, Meier IB, et al. White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimer\u2019s disease. PLoS ONE. 2018;13(5):e0195838.","journal-title":"PLoS ONE"},{"issue":"6","key":"1030_CR10","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1002\/ana.25905","volume":"88","author":"PJ Lao","year":"2020","unstructured":"Lao PJ, Gutierrez J, Keator D, Rizvi B, Banerjee A, Igwe KC, et al. Alzheimer-related cerebrovascular disease in Down syndrome. Ann Neurol. 2020;88(6):1165\u201377.","journal-title":"Ann Neurol"},{"issue":"1","key":"1030_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40478-018-0515-3","volume":"6","author":"SE Nasrabady","year":"2018","unstructured":"Nasrabady SE, Rizvi B, Goldman JE, Brickman AM. White matter changes in Alzheimer\u2019s disease: a focus on myelin and oligodendrocytes. Acta Neuropathol Commun. 2018;6(1):1\u201310.","journal-title":"Acta Neuropathol Commun"},{"issue":"7","key":"1030_CR12","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/nan.12618","volume":"46","author":"I Ferrer","year":"2020","unstructured":"Ferrer I, Andr\u00e9s-Benito P. White matter alterations in Alzheimer\u2019s disease without concomitant pathologies. Neuropathol Appl Neurobiol. 2020;46(7):654\u201372.","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"3","key":"1030_CR13","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1474-4422(10)70323-9","volume":"10","author":"N Acosta-Baena","year":"2011","unstructured":"Acosta-Baena N, Sepulveda-Falla D, Lopera-G\u00f3mez CM, Jaramillo-Elorza MC, Moreno S, Aguirre-Acevedo DC, et al. Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer\u2019s disease: a retrospective cohort study. Lancet Neurol. 2011;10(3):213\u201320.","journal-title":"Lancet Neurol"},{"issue":"3","key":"1030_CR14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1017\/S1041610292001157","volume":"4","author":"SG Sclan","year":"1992","unstructured":"Sclan SG, Reisberg B. Functional assessment staging (FAST) in Alzheimer\u2019s disease: reliability, validity, and ordinality. Int Psychogeriatr. 1992;4(3):55\u201369.","journal-title":"Int Psychogeriatr"},{"issue":"3","key":"1030_CR15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. \u201cMini-mental state\u201d: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189\u201398.","journal-title":"J Psychiatr Res"},{"issue":"4","key":"1030_CR16","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1212\/WNL.44.4.609","volume":"44","author":"KA Welsh","year":"1994","unstructured":"Welsh KA, Butters N, Mohs RC, Beekly D, Edland S, Fillenbaum G, et al. The Consortium to Establish a Registry for Alzheimer\u2019s Disease (CERAD). Part V. A normative study of the neuropsychological battery. Neurology. 1994;44(4):609.","journal-title":"Neurology"},{"issue":"1","key":"1030_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/cercor\/bhg087","volume":"14","author":"B Fischl","year":"2004","unstructured":"Fischl B, Van Der Kouwe A, Destrieux C, Halgren E, S\u00e9gonne F, Salat DH, et al. Automatically parcellating the human cerebral cortex. Cereb Cortex. 2004;14(1):11\u201322.","journal-title":"Cereb Cortex"},{"issue":"4","key":"1030_CR18","doi-asserted-by":"publisher","first-page":"3774","DOI":"10.1016\/j.neuroimage.2011.11.032","volume":"59","author":"P Schmidt","year":"2012","unstructured":"Schmidt P, Gaser C, Arsic M, Buck D, F\u00f6rschler A, Berthele A, et al. An automated tool for detection of FLAIR-hyperintense white-matter lesions in multiple sclerosis. Neuroimage. 2012;59(4):3774\u201383.","journal-title":"Neuroimage"},{"issue":"8","key":"1030_CR19","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/S1474-4422(13)70124-8","volume":"12","author":"JM Wardlaw","year":"2013","unstructured":"Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12(8):822\u201338.","journal-title":"Lancet Neurol"},{"issue":"3","key":"1030_CR20","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/S1053-8119(03)00169-1","volume":"19","author":"JA Maldjian","year":"2003","unstructured":"Maldjian JA, Laurienti PJ, Kraft RA, Burdette JH. An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. Neuroimage. 2003;19(3):1233\u20139.","journal-title":"Neuroimage"},{"issue":"5","key":"1030_CR21","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1136\/jnnp-2012-303299","volume":"84","author":"YT Quiroz","year":"2013","unstructured":"Quiroz YT, Stern CE, Reiman EM, Brickhouse M, Ruiz A, Sperling RA, et al. Cortical atrophy in presymptomatic Alzheimer\u2019s disease presenilin 1 mutation carriers. J Neurol Neurosurg Psychiatry. 2013;84(5):556\u201361.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"1030_CR22","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S1474-4422(12)70228-4","volume":"11","author":"EM Reiman","year":"2012","unstructured":"Reiman EM, Quiroz YT, Fleisher AS, Chen K, Velez-Pardo C, Jimenez-Del-Rio M, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer\u2019s disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol. 2012;11(12):1048\u201356.","journal-title":"Lancet Neurol"},{"key":"1030_CR23","doi-asserted-by":"crossref","unstructured":"Fox-Fuller JT, Torrico-Teave H, d\u2019Oleire Uquillas F, Chen K, Su Y, Chen Y, et al. Cortical thickness across the lifespan in a Colombian cohort with autosomal-dominant Alzheimer\u2019s disease: a cross-sectional study. Alzheimers Dement. 2021;13(1):e12233.","DOI":"10.1002\/dad2.12233"},{"issue":"12","key":"1030_CR24","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/S1474-4422(12)70227-2","volume":"11","author":"AS Fleisher","year":"2012","unstructured":"Fleisher AS, Chen K, Quiroz YT, Jakimovich LJ, Gomez MG, Langois CM, et al. Florbetapir PET analysis of amyloid-\u03b2 deposition in the presenilin 1 E280A autosomal dominant Alzheimer\u2019s disease kindred: a cross-sectional study. Lancet Neurol. 2012;11(12):1057\u201365.","journal-title":"Lancet Neurol"},{"issue":"3","key":"1030_CR25","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1001\/jamaneurol.2014.3314","volume":"72","author":"AS Fleisher","year":"2015","unstructured":"Fleisher AS, Chen K, Quiroz YT, Jakimovich LJ, Gomez MG, Langois CM, et al. Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study. JAMA Neurol. 2015;72(3):316\u201324.","journal-title":"JAMA Neurol"},{"key":"1030_CR26","first-page":"1","volume":"17","author":"U Gr\u00f6mping","year":"2007","unstructured":"Gr\u00f6mping U. Relative importance for linear regression in R: the package relaimpo. J Stat Softw. 2007;17:1\u201327.","journal-title":"J Stat Softw"},{"issue":"6","key":"1030_CR27","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1016\/S0002-9440(10)64688-3","volume":"158","author":"DM Mann","year":"2001","unstructured":"Mann DM, Pickering-Brown SM, Takeuchi A, Iwatsubo T, Group motFAsDPS. Amyloid angiopathy and variability in amyloid \u03b2 deposition is determined by mutation position in presenilin-1-linked Alzheimer\u2019s disease. American J Pathol. 2001;158(6):2165\u201375.","journal-title":"American J Pathol"},{"issue":"1","key":"1030_CR28","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.neurobiolaging.2014.07.019","volume":"36","author":"AM Brickman","year":"2015","unstructured":"Brickman AM, Zahodne LB, Guzman VA, Narkhede A, Meier IB, Griffith EY, et al. Reconsidering harbingers of dementia: progression of parietal lobe white matter hyperintensities predicts Alzheimer\u2019s disease incidence. Neurobiol Aging. 2015;36(1):27\u201332.","journal-title":"Neurobiol Aging"},{"issue":"2","key":"1030_CR29","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3233\/JAD-161028","volume":"57","author":"C Dallaire-Th\u00e9roux","year":"2017","unstructured":"Dallaire-Th\u00e9roux C, Callahan BL, Potvin O, Saikali S, Duchesne S. Radiological-pathological correlation in Alzheimer\u2019s disease: systematic review of antemortem magnetic resonance imaging findings. J Alzheimers Dis. 2017;57(2):575\u2013601.","journal-title":"J Alzheimers Dis"},{"key":"1030_CR30","doi-asserted-by":"publisher","first-page":"116944","DOI":"10.1016\/j.neuroimage.2020.116944","volume":"218","author":"A Moscoso","year":"2020","unstructured":"Moscoso A, Rey-Bretal D, Silva-Rodr\u00edguez J, Aldrey JM, Cort\u00e9s J, P\u00edas-Peleteiro J, et al. White matter hyperintensities are associated with subthreshold amyloid accumulation. Neuroimage. 2020;218:116944.","journal-title":"Neuroimage"},{"issue":"8","key":"1030_CR31","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1093\/brain\/awz162","volume":"142","author":"J Graff-Radford","year":"2019","unstructured":"Graff-Radford J, Arenaza-Urquijo EM, Knopman DS, Schwarz CG, Brown RD Jr, Rabinstein AA, et al. White matter hyperintensities: relationship to amyloid and tau burden. Brain. 2019;142(8):2483\u201391.","journal-title":"Brain"},{"key":"1030_CR32","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.neulet.2015.03.005","volume":"592","author":"AM Brickman","year":"2015","unstructured":"Brickman AM, Guzman VA, Gonzalez-Castellon M, Razlighi Q, Gu Y, Narkhede A, et al. Cerebral autoregulation, beta amyloid, and white matter hyperintensities are interrelated. Neurosci Lett. 2015;592:54\u20138.","journal-title":"Neurosci Lett"},{"issue":"3","key":"1030_CR33","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s00401-017-1738-2","volume":"134","author":"KE McAleese","year":"2017","unstructured":"McAleese KE, Walker L, Graham S, Moya EL, Johnson M, Erskine D, et al. Parietal white matter lesions in Alzheimer\u2019s disease are associated with cortical neurodegenerative pathology, but not with small vessel disease. Acta Neuropathol. 2017;134(3):459\u201373.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"1030_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40478-015-0240-0","volume":"3","author":"KE McAleese","year":"2015","unstructured":"McAleese KE, Firbank M, Dey M, Colloby SJ, Walker L, Johnson M, et al. Cortical tau load is associated with white matter hyperintensities. Acta Neuropathol Commun. 2015;3(1):1\u201311.","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"1030_CR35","first-page":"e12091","volume":"12","author":"M Dadar","year":"2020","unstructured":"Dadar M, Camicioli R, Duchesne S, Collins DL, Initiative AsDN. The temporal relationships between white matter hyperintensities, neurodegeneration, amyloid beta, and cognition. Alzheimers Dement. 2020;12(1):e12091.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"1030_CR36","doi-asserted-by":"publisher","first-page":"e313","DOI":"10.1212\/WNL.0000000000005864","volume":"91","author":"JF Strain","year":"2018","unstructured":"Strain JF, Smith RX, Beaumont H, Roe CM, Gordon BA, Mishra S, et al. Loss of white matter integrity reflects tau accumulation in Alzheimer disease defined regions. Neurology. 2018;91(4):e313\u20138.","journal-title":"Neurology"},{"issue":"1","key":"1030_CR37","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/glia.20734","volume":"57","author":"MK Desai","year":"2009","unstructured":"Desai MK, Sudol KL, Janelsins MC, Mastrangelo MA, Frazer ME, Bowers WJ. Triple-transgenic Alzheimer\u2019s disease mice exhibit region-specific abnormalities in brain myelination patterns prior to appearance of amyloid and tau pathology. Glia. 2009;57(1):54\u201365.","journal-title":"Glia"},{"key":"1030_CR38","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.nicl.2015.06.007","volume":"8","author":"FU Fischer","year":"2015","unstructured":"Fischer FU, Wolf D, Scheurich A, Fellgiebel A, Initiative AsDN. Altered whole-brain white matter networks in preclinical Alzheimer\u2019s disease. NeuroImage Clin. 2015;8:660\u20136.","journal-title":"NeuroImage Clin"},{"issue":"5","key":"1030_CR39","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.cell.2015.10.067","volume":"163","author":"Z Zhao","year":"2015","unstructured":"Zhao Z, Nelson AR, Betsholtz C, Zlokovic BV. Establishment and dysfunction of the blood-brain barrier. Cell. 2015;163(5):1064\u201378.","journal-title":"Cell"},{"issue":"4","key":"1030_CR40","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1161\/STROKEAHA.107.497438","volume":"39","author":"CM Holland","year":"2008","unstructured":"Holland CM, Smith EE, Csapo I, Gurol ME, Brylka DA, Killiany RJ, et al. Spatial distribution of white-matter hyperintensities in Alzheimer disease, cerebral amyloid angiopathy, and healthy aging. Stroke. 2008;39(4):1127\u201333.","journal-title":"Stroke"},{"issue":"2","key":"1030_CR41","doi-asserted-by":"publisher","first-page":"fcaa132","DOI":"10.1093\/braincomms\/fcaa132","volume":"2","author":"KK Laing","year":"2020","unstructured":"Laing KK, Simoes S, Baena-Caldas GP, Lao PJ, Kothiya M, Igwe KC, et al. Cerebrovascular disease promotes tau pathology in Alzheimer\u2019s disease. Brain Commun. 2020;2(2):fcaa132.","journal-title":"Brain Commun"},{"issue":"9","key":"1030_CR42","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1212\/WNL.43.9.1683","volume":"43","author":"F Fazekas","year":"1993","unstructured":"Fazekas F, Kleinert R, Offenbacher H, Schmidt R, Kleinert G, Payer F, et al. Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology. 1993;43(9):1683.","journal-title":"Neurology"},{"issue":"3","key":"1030_CR43","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nrneurol.2015.10","volume":"11","author":"ND Prins","year":"2015","unstructured":"Prins ND, Scheltens P. White matter hyperintensities, cognitive impairment and dementia: an update. Nat Rev Neurol. 2015;11(3):157\u201365.","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"1030_CR44","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362.","journal-title":"Alzheimers Dement"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-022-01030-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-022-01030-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-022-01030-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T15:11:25Z","timestamp":1656515485000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-022-01030-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,29]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1030"],"URL":"https:\/\/doi.org\/10.1186\/s13195-022-01030-7","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,29]]},"assertion":[{"value":"4 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Study procedures were carried in accordance with ethical standards from the Helsinki Declaration and all participants provided informed consent. Study procedures were reviewed and approved by the Bioethics Committee of the University of Antioquia (Medell\u00edn, Colombia) and the Institutional Review Board of the Massachusetts General Hospital (USA).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"FL reports funding for the Colombian API Registry from Genentech. YTQ reports consulting fees from Biogen. The other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"89"}}